PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Both yoy net incomes decline, with RVPH at -61.68%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.01%
D&A growth of 3.01% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
9.00%
Less SBC growth vs. RVPH's 124.84%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
715.46%
Slight usage while RVPH is negative at -128.76%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
AP growth well above RVPH's 42.02%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
304.81%
Some yoy usage while RVPH is negative at -262.16%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
412.12%
Some yoy increase while RVPH is negative at -18.95%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.59%
Some CFO growth while RVPH is negative at -68.97%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-4.76%
We cut debt repayment yoy while RVPH is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.